• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Annexon, Inc. - common stock (NQ:ANNX)

4.890 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35
Open 4.890
Bid (Size) 4.910 (100)
Ask (Size) 5.200 (600)
Prev. Close 4.890
Today's Range 4.890 - 4.890
52wk Range 2.030 - 7.180
Shares Outstanding 47,722,995
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Annexon (ANNX) Q2 2026 Earnings Call Transcript ↗
August 19, 2026
GBS and geographic atrophy programs advance toward 2026-2027 regulatory submissions. 
Via The Motley Fool
Topics Earnings
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
August 17, 2026
From Annexon Biosciences
Via GlobeNewswire

Performance

YTD
+4.3%
+4.3%
1 Month
-6.9%
-6.9%
3 Month
-7.0%
-7.0%
6 Month
-9.9%
-9.9%
1 Year
+136.2%
+136.2%

More News

Read More
News headline image
Annexon Q2 Earnings Call Highlights ↗
August 12, 2026
Via MarketBeat
Topics Earnings
News headline image
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
August 12, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch of Open-Label Extension Study
August 12, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D., M.M.S. to its Board of Directors
August 10, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week
August 06, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
July 30, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
July 16, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Present Phase 2 ARCHER Baseline Characteristics Associated with Confirmed Best Corrected Visual Acuity 15-Letter Loss in Patients with Geographic Atrophy at ASRS 2026
July 14, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
June 16, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Eyes ‘Win Season’ With Q4 Vision Trial Data, GBS Filings Ahead ↗
June 09, 2026
Via MarketBeat
News headline image
Annexon Maps 3 Big Pipeline Catalysts Ahead of Q4 Vision-Drug Readout ↗
June 04, 2026
Via MarketBeat
News headline image
Annexon to Participate in Upcoming June Investor Conferences
May 27, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
May 18, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Highlights Q4 Geographic Atrophy Data, GBS Filing Plans at BofA Conference ↗
May 14, 2026
Via MarketBeat
News headline image
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
May 07, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Present at the Bank of America Securities Health Care Conference 2026
May 06, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Biogen Acquires Apellis Pharmaceuticals in $5.6 Billion Deal After Clinical Success
April 01, 2026
Via MarketMinute
News headline image
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
March 30, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
March 16, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Biosciences to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon to Host In-Person and Virtual KOL Event to Discuss Vonaprument for the Treatment of Geographic Atrophy
February 17, 2026
From Annexon Biosciences
Via GlobeNewswire
News headline image
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
January 16, 2026
From Annexon Biosciences
Via GlobeNewswire
Curious about the stocks that are showing activity after the closing bell on Monday? ↗
January 12, 2026
Via Chartmill

Frequently Asked Questions

Is Annexon, Inc. - common stock publicly traded?
Yes, Annexon, Inc. - common stock is publicly traded.
What exchange does Annexon, Inc. - common stock trade on?
Annexon, Inc. - common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Annexon, Inc. - common stock?
The ticker symbol for Annexon, Inc. - common stock is ANNX on the Nasdaq Stock Market
What is the current price of Annexon, Inc. - common stock?
The current price of Annexon, Inc. - common stock is 4.890
When was Annexon, Inc. - common stock last traded?
The last trade of Annexon, Inc. - common stock was at 09/01/26 04:00 PM ET
What is the market capitalization of Annexon, Inc. - common stock?
The market capitalization of Annexon, Inc. - common stock is 233.37M
How many shares of Annexon, Inc. - common stock are outstanding?
Annexon, Inc. - common stock has 233M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap